Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Central Venous Access Clear all
Completed Phase 2 Interventional

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

NCT00073515
View directory record Official record
Conditions
Catheters, Indwelling
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 10, 2026, 7:09 AM EDT
Recruiting Phase 4 Interventional

Central Line Study

NCT05534971
View directory record Official record
Conditions
Shock
Interventions
Central venous catheter insertion
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Completed No phase listed Observational Results available

Compass Device CVC Trial

NCT03056859
View directory record Official record
Conditions
Blood Pressure
Interventions
Extravascular blood pressure transducer
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

NCT00611858
View directory record Official record
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-Fluorouracil, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 10, 2026, 7:09 AM EDT
Not listed Not applicable Interventional

Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

NCT01271881
View directory record Official record
Conditions
Hemodialysis
Interventions
PTA alone without use of the GORE VIABAHN, GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Other · Device
Lead sponsor
American Access Care
Other
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Flushing, New York • The Bronx, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 10, 2026, 7:09 AM EDT
Not listed Not applicable Interventional

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

NCT01213914
View directory record Official record
Conditions
Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions
An FDA approved continuous renal replacement device, Control Group
Device · Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 1 Interventional

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

NCT00670410
View directory record Official record
Conditions
Neuroblastoma
Interventions
Related donor transplant, Cord blood transplant, Busulfan, Thymoglobulin, Fludarabine
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

The Angel® Catheter Pivotal Clinical Trial

NCT02186223
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions
The Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers

NCT03547635
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care
Other · Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 4 Interventional Results available

Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock

NCT00535821
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Esophageal Doppler monitoring - CardioQ, Deltex Inc, Central line with CVP and continuous ScvO2 monitoring
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Loma Linda, California • Worcester, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 10, 2026, 7:09 AM EDT
Recruiting Phase 2 Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT03418038
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
4
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

Pediatric Ethanol Lock Therapy Study.

NCT00948441
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
25% ethanol, heparin lock
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 10, 2026, 7:09 AM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 10, 2026, 7:09 AM EDT
Terminated Phase 4 Interventional

Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

NCT01623583
View directory record Official record
Conditions
Needle Phobia, Phobic Disorders
Interventions
Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
Other
Lead sponsor
Davita Clinical Research
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rancho Cordova, California • Sacramento, California • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

A Prospective Trial of Ultrasound Versus Landmark Guided Central Venous Access in the Pediatric Population

NCT01680666
View directory record Official record
Conditions
Need for Central Venous Access
Interventions
central line placement, Ultrasound
Procedure · Device
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Palo Alto, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Antifungal Locks to Treat Fungal-related Central Line Infections

NCT00936910
View directory record Official record
Conditions
Central Line Fungal Infections
Interventions
amphotericin B liposomal (Ambisome)
Drug
Lead sponsor
Bill McGhee
Other
Eligibility
30 Days to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 10, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis

NCT04399941
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Venography, Intravascular ultrasound (IVUS), Image processing
Diagnostic Test · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
View directory record Official record
Conditions
Multiple Myeloma, Primary Amyloidosis
Interventions
Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Platelet Transfusion During Neonatal Open Heart Surgery

NCT03045068
View directory record Official record
Conditions
Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass, Platelet Transfusion, Arrythmia, Cardiac, Mortality
Interventions
Platelet Transfusion, FFP and Cryoprecipitate, PRBC and cell saver Transfusion, Factor Concentrate (Bebulin)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 3 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

NCT04261686
View directory record Official record
Conditions
Arteriovenous Fistula
Interventions
Covera Vascular Covered Stent
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • New Haven, Connecticut • Westmont, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 10, 2026, 7:09 AM EDT
Recruiting Phase 3 Interventional

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277
View directory record Official record
Conditions
Prostate Cancer
Interventions
AAA817, ARPI, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
38
States / cities
Homewood, Alabama • Orange, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Not listed Not applicable Interventional

Amnioband and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers

NCT02609594
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Weekly application of Amnioband, Biweekly application of Amnioband, Standard of Care
Other
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Boston, Massachusetts • Brick, New Jersey • Elmer, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 10, 2026, 7:09 AM EDT
Active, not recruiting Not applicable Interventional

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04646226
View directory record Official record
Conditions
End-Stage Kidney Disease, Hemodialysis Complication
Interventions
AV graft, surgical intervention for creation of a fistula
Device · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 10, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis

NCT01257438
View directory record Official record
Conditions
Restenosis
Interventions
Fluency Plus Endovascular Stent Graft, Percutaneous Transluminal Angioplasty only
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 10, 2026, 7:09 AM EDT